Recent Advances in Validating MDM2 as a Cancer Target

E-ISSN： 1875-5992|9|8|882-903

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.9, Iss.8, 2009-10, pp. : 882-903

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Validating the meta-analytical results on MDM2, CASP8, XRCC3 polymorphisms and breast cancer risk: examination of Hardy–Weinberg Equilibrium

By Sergentanis Theodoros

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 819-823

Springer Publishing Company

Access to resources Recommend Favorite

Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wildtype p53 breast cancer cells

International Journal of Oncology, Vol. 43, Iss. 6, 2013-01 ,pp. : 1935-1942

Spandidos Publications

Access to resources Recommend Favorite

MDM2 sensitizes a human ovarian cancer cell line

By Mi R.-R. Ni H.

Gynecologic Oncology, Vol. 90, Iss. 2, 2003-08 ,pp. : 238-244

Elsevier

Access to resources Recommend Favorite

Recent advances in the management of colorectal cancer

By Van Cutsem E. Dicato M. Wils J.

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2302-2309

Elsevier

Access to resources Recommend Favorite

Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer

By Hori M.

Breast Cancer Research and Treatment, Vol. 71, Iss. 1, 2002-01 ,pp. : 77-84

Springer Publishing Company

Access to resources Recommend Favorite